Gopinadhan N. Anilkumar;Yuefei Shao;Douglas W. Hobbs;Seong Heon Kim;Michael K. C. Wong;Joseph A. Kozlowski;Stuart B. Rosenblum;Qingbei Zeng;Brian F. McGuinness
发明人:
Seong Heon Kim,Gopinadhan N. Anilkumar,Michael K. C. Wong,Qingbei Zeng,Stuart B. Rosenblum,Joseph A. Kozlowski,Yuefei Shao,Brian F. McGuinness,Douglas W. Hobbs
申请号：
US12952994
公开号：
US08207170B2
申请日:
2010.11.23
申请国别(地区):
US
年份:
2012
代理人:
摘要：
The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1:or a pharmaceutically acceptable salt, solvate or ester thereof, wherein the various moieties are defined herein. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.
